Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
KRAS mutant
|
Advanced Solid Tumor
|
predicted - sensitive |
APS-2-79 + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of several KRAS mutant cancer cell lines in culture (PMID: 27556948).
|
27556948
|
KRAS G12S
|
lung cancer
|
sensitive |
APS-2-79 + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).
|
27556948
|
KRAS G13D
|
colon cancer
|
sensitive |
APS-2-79 + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a colon cancer cell line harboring KRAS G13D in culture (PMID: 27556948).
|
27556948
|